Overview

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
This drug-drug interaction (DDI) study had been designed to investigate the effect of a strong CYP 3A index fan-inducer rifampicin on the pharmacokinetics of SHR1459 in Chinese healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Rifampin